Sepsis, October 15 edition

In a difference-in-differences analysis of 521,493 admissions across two academic medical centers, linezolid restriction policies reduced linezolid use by 27% and linezolid resistance by 41%. Overall mortality did not increase, but mortality rose by 4.7 percentage points among VRE-screen-positive patients, with larger increases in bacteremia or sepsis.

Impact: This large, real-world quasi-experimental study quantifies both the benefit and the potential unintended harm of antibiotic restriction. It directly supports stewardship policies while showing that resistance reduction must be balanced against timely treatment for patients at high risk of VRE infection.

Clinical Implications: Hospitals can use prior authorization and post-prescription review to reduce linezolid exposure and resistance, but should incorporate VRE screening, suspected bacteremia, and sepsis severity into exception pathways to prevent delayed effective therapy.

Future Directions: Prospective stewardship studies should test screening-informed exception criteria, measure time to active therapy, and evaluate whether targeted safeguards preserve mortality outcomes while maintaining reductions in antibiotic use and resistance.

Using septic mice, macrophages, and a human sepsis transcriptomic dataset, the study identified a DNMT-mediated hypermethylation of the Sdhd promoter that reduces SDHD expression, promotes succinate accumulation, and activates oxidative mitochondrial DNA-associated NLRP3 pyroptosis. Sdhd overexpression and pharmacological DNMT inhibition with SGI-1027 reduced pyroptosis, lung injury, and mortality in mice.

Impact: This study links epigenetic silencing, mitochondrial metabolism, innate immune activation, and fatal lung injury in a coherent mechanistic pathway. It provides a potentially druggable upstream target while demonstrating effects across patient data, cellular experiments, and in vivo models.

Clinical Implications: The DNMT-SDHD-succinate axis could support development of host-directed therapies for sepsis-associated acute lung injury, but therapeutic-window, infection-control, toxicity, and human target-engagement studies are required before clinical translation.

Future Directions: Future studies should validate SDHD methylation and succinate as biomarkers in prospective sepsis cohorts, define the therapeutic window after infection onset, assess host defense and organ-specific toxicity, and test selective DNMT-SDHD pathway modulation in clinically relevant models.

Plasma tiRNA-Pro-AGG-001 declined progressively from healthy controls to pediatric sepsis and septic shock and also decreased in plasma and organs of CLP mice. Prophylactic agomir administration improved survival and reduced lung, liver, and kidney injury, while mechanistic studies implicated direct targeting of Notch1 and suppression of Notch1/NF-kB signaling and M1-like macrophage activation.

Impact: The paper integrates a clinically measurable small-RNA signature with a mechanistic host-response pathway and experimental intervention. It is particularly relevant to pediatric precision medicine, although the therapeutic evidence is currently limited to prophylactic animal treatment.

Clinical Implications: tiRNA-Pro-AGG-001 could be developed for severity stratification or prognosis assessment in pediatric sepsis, and the Notch1/NF-kB axis may support host-directed therapy. Clinical use requires prospective validation and treatment-after-onset studies.

Future Directions: Prospective multicenter pediatric cohorts should validate diagnostic and prognostic performance, establish age- and pathogen-specific reference ranges, and test therapeutic-window administration after sepsis onset in clinically relevant models before early-phase clinical trials.